Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Cancer Related Cognitive Decline × Trastuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 527 Stomach Neoplasms 61 Neoplasm Metastasis 50 Neoplasms 33 Breast Neoplasms, Male 27 HER2-positive Breast Cancer 26 Colorectal Neoplasms 24 Brain Neoplasms 21 Esophageal Neoplasms 19 Carcinoma, Non-Small-Cell Lung 17 Inflammatory Breast Neoplasms 15 Triple Negative Breast Neoplasms 11 Pancreatic Neoplasms 11 Ovarian Neoplasms 9 Endometrial Neoplasms 9 Colonic Neoplasms 9 Rectal Neoplasms 8 Urinary Bladder Neoplasms 7 Salivary Gland Neoplasms 7 Prostatic Neoplasms 7 Lung Neoplasms 7 Gallbladder Neoplasms 7 Adenocarcinoma Of Esophagus 7 Adenocarcinoma 7 Sarcoma 6 Pathologic Complete Response 6 Biliary Tract Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Breast Diseases 5 Uterine Cervical Neoplasms 4

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡